For Key Opinion Leaders (KOLs)

Hematologists, Oncologists, Autoimmunity Experts, Academic Researchers, Biologists, etc.

Our lead molecule, AVM0703, lympho-ablates both T and B lymphocytes for “immune reset” via receptor-mediated induction of caspase-dependent apoptosis. AVM0703 spares neutrophils, platelets, RBCs and stem cells. 

For Patients and their Loved Ones

For Relapsed/Refractory Lymphocytic Blood Cancer and Non-responding Autoimmune Patients and their Loved Ones

We at AVM believe that there should be a treatment option that allows you to have a good quality of life with your loved ones without exhausting your financials.

AVM0703 Has the Most Favorable Lymphodepletion Profile

Cy/Flu

  • No Bone Marrow Redistribution
  • Deplete Peripheral Blood Lymph
  • Decrease Adoptive Cell Transfer (ACT) Binding in Spleen
  • Decrease Thymocytes
  • Increase in IL-2, IL-7, IL-12 and IL-15
  • Decrease Endogenous HSCs and MSCs
  • Increase in IL-6 and GM-CSF
  • Deplete Neutrophils, Platelets and RBCs
  • CRS, neuroedema, angiodema, fatal infusion reactions

AVM0703

  • No Bone Marrow Redistribution
  • Deplete Peripheral Blood Lymph
  • Decrease Adoptive Cell Transfer (ACT) Binding in Spleen
  • Decrease Thymocytes
  • Increase in IL-2, IL-7, IL-12 and IL-15
  • Increase Endogenous HSCs and MSCs
  • No Increase in IL-6 and GM-CSF
  • Spares Neutrophils, Platelets and RBCs
  • No CRS, neuroedema, angiodema, fatal infusion reactions

Temodar, Rituximab, etc.

  • No Bone Marrow Redistribution
  • Deplete Peripheral Blood Lymph
  • Decrease Adoptive Cell Transfer (ACT) Binding in Spleen
  • Decrease Thymocytes
  • Increase in IL-2, IL-7, IL-12 and IL-15
  • Decrease Endogenous HSCs and MSCs
  • Increase in IL-6 and GM-CSF
  • Deplete Neutrophils, Platelets and RBCs
  • CRS, neuroedema, angiodema, fatal infusion reactions